Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer

Article Obstetrics & Gynecology

Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer

Shannon N. Westin et al.

GYNECOLOGIC ONCOLOGY (2022)

Article Oncology

XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a

Jingya Wang et al.

Summary: Combining a PARP inhibitor with an XPO1 inhibitor significantly improves efficacy and tolerability in treating small cell lung cancer, restoring the balance and activity of FOXO3a. This dual inhibition provides a new therapeutic approach for SCLC, warranting further investigation in potential clinical trials.

CANCER LETTERS (2021)

添加到收藏夹

Article Oncology

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts

Joshua C. Rosen et al.

Summary: The study found that KRASmut lung adenocarcinomas are sensitive to the XPO1 inhibitor Selinexor, with better efficacy than the clinical MEK1/2 inhibitor Trametinib. TP53 mutations may impact the drug response. Mining genome-wide dropout datasets identified XPO1 as a universal cancer cell dependency, but targeted kinase inhibitors were more effective in KRASWT PDX models.

TRANSLATIONAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology